Comparing two blood thinners for stent treatment of brain aneurysm
Part of Brain & nervous system, Heart & circulation clinical trials.
This study compares two common blood-thinner combinations to see which one works better at preventing clots during stent placement for an unruptured brain aneurysm. It is designed for people whose bodies process these medications normally, with the goal of finding the safest and most effective option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an unruptured (not yet burst) brain aneurysm and are scheduled for a procedure using a stent to treat it.
- You are 20 to 70 years old.
- You are generally independent in daily activities (able to walk and care for yourself).
- Your gene for handling certain blood thinners (CYP2C19) must be the normal type, which can be checked by a blood test.
- You have not had a previous stroke, heart attack, or other major cardiovascular event.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares using a genetic test to choose between two anti-clot medications (clopidogrel and ticagrelor) versus the usual approach of giving clopidogrel alone. It aims to see if personalized treatment can better prevent strokes in people with narrowed brain arteries.
This trial tests whether a combination of two or three anti-platelet medicines (like aspirin, clopidogrel, or cilostazol) is safe and works better than one alone for people who had a stroke from a narrowed artery. The goal is to prevent another stroke.
This trial tests whether the drug ticagrelor, which helps prevent blood clots, can reduce the risk of a stroke occurring days after a mild form of bleeding in the brain. It is given as an add-on to the standard treatment for the bleeding aneurysm.
This trial tests switching from a standard blood thinner (clopidogrel) to a lower dose of a stronger one (prasugrel) in people who have had a stent placed and are at high risk for both bleeding and heart problems. The goal is to see if the switch better prevents clots while keeping bleeding risks low.
This study tests whether a common blood thinner (apixaban) alone is as safe and effective as combining it with another drug (clopidogrel) to prevent future strokes in people who have both atrial fibrillation and narrowing in the arteries leading to the brain. It aims to find the best way to reduce stroke risk while minimizing bleeding.
This trial compares two common blood-thinning medications (prasugrel vs ticagrelor) and two treatment durations (short 1–3 months vs standard 12 months) after a heart attack treated with stents. It aims to find the most effective and safest anti-clotting strategy for patients.
Hear when a new Antiplatelet Drugs trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.